<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cvs Group Plc — News on 6ix</title>
<link>https://6ix.com/company/cvs-group-plc</link>
<description>Latest news and press releases for Cvs Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:46:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cvs-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57ca1beedb30cb6f89119.webp</url>
<title>Cvs Group Plc</title>
<link>https://6ix.com/company/cvs-group-plc</link>
</image>
<item>
<title>Non-Executive Director Appointment</title>
<link>https://6ix.com/company/cvs-group-plc/news/non-executive-director-appointment-42</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/non-executive-director-appointment-42</guid>
<pubDate>Tue, 21 Apr 2026 11:46:00 GMT</pubDate>
<description>CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director, effective May 1, 2026, bringing extensive experience in people leadership, organisation design, and international expansion from her previous roles at companies like FeverTree Drinks, Deliveroo, Gymshark, Tate & Lyle, and Dyson. Ms. Hagan will join the Group's Remuneration, Audit and Risk, and Nomination Committees, enhancing the board's expertise in listed company operations and people development.
</description>
</item>
<item>
<title>Standard form for notification of major holdings</title>
<link>https://6ix.com/company/cvs-group-plc/news/standard-form-for-notification-of-major-holdings-74</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/standard-form-for-notification-of-major-holdings-74</guid>
<pubDate>Mon, 20 Apr 2026 15:45:00 GMT</pubDate>
<description>BlackRock, Inc. has reported a change in its major holding in CVS Group plc, with its total voting rights and financial instruments now standing at 6.63%, down from a previous 5.26%. This change, effective April 17, 2026, resulted in BlackRock holding 4,930,000 voting rights attached to shares and an additional 1,700,000 voting rights through financial instruments, specifically securities lending. The total number of voting rights held by BlackRock in CVS Group plc is now 4,660,248.
</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/cvs-group-plc/news/total-voting-rights-914</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/total-voting-rights-914</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>CVS Group plc has announced its total voting rights as of 31 March 2026, stating that the company's issued share capital comprises 70,156,883 ordinary shares of 0.2p each, with each share carrying one voting right. The company holds no shares in treasury, resulting in a total of 70,156,883 voting rights. This figure serves as the denominator for shareholders to determine notification requirements under the FCA's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>CEO retirement</title>
<link>https://6ix.com/company/cvs-group-plc/news/ceo-retirement-2</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/ceo-retirement-2</guid>
<pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
<description>CVS Group plc announced that CEO Richard Fairman will retire for personal reasons, having led the company since 2019 through significant growth, international expansion into Australia, and a move to the London Stock Exchange's Main Market with FTSE 250 inclusion. During his tenure, the Group grew to approximately 9,000 employees, including 2,500 vets and 3,300 nurses, with EBITDA nearly tripling across its roughly 475 practices. Fairman will remain in his role until a successor is appointed to e</description>
</item>
<item>
<title>Non-Executive Director Changes</title>
<link>https://6ix.com/company/cvs-group-plc/news/non-executive-director-changes-12</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/non-executive-director-changes-12</guid>
<pubDate>Wed, 25 Mar 2026 07:00:00 GMT</pubDate>
<description>CVS Group plc announces the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors, effective April 1, 2026, and the retirement of Deborah Kemp on June 30, 2026. Helen Keays will also assume the role of Chair Designate of the Remuneration Committee from April 1, 2026, and formally become Chair on July 1, 2026. David Wilton, the current Chair, will succeed Richard Gray as Chair of the Nomination Committee on April 1, 2026. These changes are expected to strengthen the b</description>
</item>
<item>
<title>Response to CMA Summary Final Decision Report</title>
<link>https://6ix.com/company/cvs-group-plc/news/response-to-cma-summary-final-decision-report</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/response-to-cma-summary-final-decision-report</guid>
<pubDate>Tue, 24 Mar 2026 07:13:00 GMT</pubDate>
<description>CVS Group plc has responded to the Competition and Markets Authority's (CMA) final decision report regarding the veterinary services market, welcoming the certainty provided after over two and a half years of scrutiny. The CMA's final decision does not introduce new remedies beyond the provisional announcement, and CVS is comfortable with the workable remedies, including an increased fee cap of £21 for the first prescribed drug and an additional £12.50 for subsequent drugs. The company has alrea</description>
</item>
<item>
<title>Interim Results</title>
<link>https://6ix.com/company/cvs-group-plc/news/interim-results-620</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/interim-results-620</guid>
<pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
<description>CVS Group plc reported a 5.8% increase in revenue to £356.9m for the six months ended December 31, 2025, with like-for-like sales growth of 2.7% despite softer UK market conditions. Adjusted EBITDA rose by 3.9% to £67.7m, maintaining a 19.0% margin, while profit before tax from continuing operations decreased by 4.4% to £15.2m due to increased depreciation, business combination costs, and exceptional costs related to the CMA process and LSE listing. The company's leverage increased to 1.41x foll</description>
</item>
<item>
<title>Readmission - CVS Group Plc</title>
<link>https://6ix.com/company/cvs-group-plc/news/readmission-cvs-group-plc</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/readmission-cvs-group-plc</guid>
<pubDate>Thu, 29 Jan 2026 08:00:00 GMT</pubDate>
<description>CVS Group PLC's ordinary shares of 0.2 pence each have been cancelled from trading on AIM, effective January 29, 2026, following a transfer to the Main Market. This move signifies a change in the company's listing venue, which could impact investor access and trading dynamics.
Disclaimer*</description>
</item>
<item>
<title>Response to DEFRA consultation</title>
<link>https://6ix.com/company/cvs-group-plc/news/response-to-defra-consultation</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/response-to-defra-consultation</guid>
<pubDate>Wed, 28 Jan 2026 07:08:00 GMT</pubDate>
<description>CVS Group plc welcomes the Department for Environment, Food and Rural Affairs' announcement of a consultation on reforms to the Veterinary Surgeons Act 1966, a move recommended by the Competition and Markets Authority. CVS believes these reforms will enhance consumer confidence and regulation, including practice-level accountability and expanding the role of Registered Veterinary Nurses. The Group anticipates delivering FY2026 results in line with expectations.
Disclaimer*</description>
</item>
<item>
<title>Publication of Prospectus and Trading Update</title>
<link>https://6ix.com/company/cvs-group-plc/news/publication-of-prospectus-and-trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/publication-of-prospectus-and-trading-update</guid>
<pubDate>Fri, 23 Jan 2026 12:19:00 GMT</pubDate>
<description>CVS Group plc has published a prospectus for its admission to the Main Market of the London Stock Exchange on January 29, 2026, with no new funds being raised. The company reported a 5.8% increase in revenue to £356.9 million for the six months ended December 31, 2025, with like-for-like sales up 2.7%. Adjusted EBITDA rose 3.9% to £67.7 million, though the adjusted EBITDA margin slightly decreased to 19.0%. Investments in technology and equipment totalled £17.5 million. Net bank borrowings incre</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/cvs-group-plc/news/transaction-in-own-shares-778</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/transaction-in-own-shares-778</guid>
<pubDate>Thu, 22 Jan 2026 07:00:00 GMT</pubDate>
<description>CVS Group plc has announced the purchase of 52,278 ordinary shares on January 21, 2026, as part of its share buyback program, with prices ranging from 1,304.00 pence to 1,340.00 pence per share, averaging 1,319.53 pence. These shares will be cancelled, reducing the total number of issued ordinary shares to 70,207,791, which will serve as the new denominator for shareholder notification calculations. Since the program's inception, CVS has repurchased a total of 1,532,992 ordinary shares at a weig</description>
</item>
<item>
<title>Block Listing Interim Review</title>
<link>https://6ix.com/company/cvs-group-plc/news/block-listing-interim-review-321</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/block-listing-interim-review-321</guid>
<pubDate>Mon, 12 Jan 2026 07:00:00 GMT</pubDate>
<description>CVS Group plc has provided an interim review of its block listing arrangements for the period from July 12, 2025, to January 12, 2026. During this period, 599 ordinary shares were issued under the CVS Group SAYE Plan, reducing the unallotted balance to 337,366 shares, while the CVS Long Term Incentive Plan had no shares issued, maintaining its unallotted balance at 68,393 shares. The company originally listed 350,000 ordinary shares for the SAYE plan on December 30, 2021, and 120,000 ordinary sh</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/cvs-group-plc/news/directorpdmr-shareholding-1094</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/directorpdmr-shareholding-1094</guid>
<pubDate>Tue, 06 Jan 2026 09:34:00 GMT</pubDate>
<description>CVS Group plc announced that Richard Gray, a Non-executive Director, purchased 2,000 ordinary shares at a price of 1,276.96 pence per share on January 5, 2026. Following this transaction, Richard Gray's total interest in the company, including associated persons, now stands at 9,600 ordinary shares, representing 0.014% of the total voting rights. This on-market purchase on the London Stock Exchange's AIM market indicates a director's continued investment in the company.
Disclaime</description>
</item>
<item>
<title>Update on move to the Main Market</title>
<link>https://6ix.com/company/cvs-group-plc/news/update-on-move-to-the-main-market-2</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/update-on-move-to-the-main-market-2</guid>
<pubDate>Thu, 11 Dec 2025 07:00:00 GMT</pubDate>
<description>CVS Group plc has announced that its admission to the Main Market of the London Stock Exchange is expected to occur at 8:00 a.m. on January 29, 2026, with its AIM listing simultaneously cancelled. The last day of trading on AIM will be January 28, 2026. This move to the Main Market is an introduction of existing ordinary shares and is contingent upon regulatory approvals, including the FCA's approval of a Prospectus and the shares being admitted to the ESCC segment of the Official List. Sharehol</description>
</item>
<item>
<title>PDMR Dealing</title>
<link>https://6ix.com/company/cvs-group-plc/news/pdmr-dealing-77</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/pdmr-dealing-77</guid>
<pubDate>Mon, 08 Dec 2025 17:39:00 GMT</pubDate>
<description>CVS Group plc announced that Paul Higgs, Director and Chief Veterinary Officer, purchased 1,235 ordinary shares for 1,213.996 pence each, increasing his total holding to 4,931 shares representing 0.007 per cent of voting rights. Additionally, Joanne Shaw, Non-Executive Director, purchased 825 ordinary shares for 1,210.679 pence each, bringing her total interest to 2,387 shares, or 0.003 per cent of voting rights. These on-market purchases occurred on 5 December 2025 on the London Stock Exchange'</description>
</item>
<item>
<title>SAYE Option Scheme & PDMR Dealing</title>
<link>https://6ix.com/company/cvs-group-plc/news/saye-option-scheme-and-pdmr-dealing</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/saye-option-scheme-and-pdmr-dealing</guid>
<pubDate>Fri, 28 Nov 2025 16:34:00 GMT</pubDate>
<description>CVS Group plc announced that its Executive Directors, Richard Fairman, Robin Alfonso, and Paul Higgs, have been granted options under the company's Save As You Earn (SAYE) share scheme. A total of 370,637 SAYE scheme options were granted on November 26, 2025, representing 0.52% of the issued ordinary share capital, with an exercise price of 1,136 pence per share, a 10% discount to the average closing price prior to November 1, 2025. These options are exercisable from January 1, 2029.
</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/cvs-group-plc/news/result-of-agm-1135</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/result-of-agm-1135</guid>
<pubDate>Tue, 18 Nov 2025 14:50:00 GMT</pubDate>
<description>CVS Group plc announced that all resolutions were passed at its Annual General Meeting, with resolutions 1 to 14 approved as ordinary and resolutions 15 to 18 as special. Notably, approximately 22% of votes were cast against resolution 3 concerning the Remuneration Report, prompting the company to consult with relevant shareholders to understand the reasons and provide an update within six months.
Disclaimer*</description>
</item>
<item>
<title>Commencement of Share Buyback Programme</title>
<link>https://6ix.com/company/cvs-group-plc/news/commencement-of-share-buyback-programme-33</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/commencement-of-share-buyback-programme-33</guid>
<pubDate>Fri, 24 Oct 2025 06:06:00 GMT</pubDate>
<description>CVS Group plc announced the commencement of a share buyback programme, allocating up to £20 million to purchase ordinary shares of 0.2 pence each. The purpose of this programme is to return surplus capital to shareholders and reduce the Group's share capital, with all repurchased shares to be cancelled. Berenberg will manage the purchases as a riskless principal, operating on a non-discretionary basis within pre-set parameters. The buyback programme is expected to be completed in Q1 of calendar </description>
</item>
<item>
<title>Posting of Annual Report & Notice of AGM</title>
<link>https://6ix.com/company/cvs-group-plc/news/posting-of-annual-report-and-notice-of-agm-193</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/posting-of-annual-report-and-notice-of-agm-193</guid>
<pubDate>Fri, 17 Oct 2025 06:00:00 GMT</pubDate>
<description>CVS Group plc announced that its Annual General Meeting (AGM) will be held on November 18, 2025, at 11:00 am. The Annual Report and Accounts for the financial year ended June 30, 2025, along with the Notice of AGM and proxy form, were sent to shareholders on October 17, 2025. Shareholders who opted for electronic communication have been notified that these documents are available on the company's website. The company encourages shareholders to submit a proxy vote in advance of the AGM, appointin</description>
</item>
<item>
<title>Response to CMA provisional decision announcement</title>
<link>https://6ix.com/company/cvs-group-plc/news/response-to-cma-provisional-decision-announcement</link>
<guid isPermaLink="true">https://6ix.com/company/cvs-group-plc/news/response-to-cma-provisional-decision-announcement</guid>
<pubDate>Wed, 15 Oct 2025 06:35:00 GMT</pubDate>
<description>CVS Group plc has responded to the Competition and Markets Authority's (CMA) provisional decision announcement regarding the veterinary market investigation. CVS welcomes the certainty and will respond to the decision and proposed remedies in writing, with a hearing scheduled for December 2025, anticipating the final decision in March 2026. The initial 28 remedies proposed in May 2025 have been refined to 21, with no new remedies introduced. CVS will collaborate with the CMA to refine the remedi</description>
</item>
</channel>
</rss>